NASDAQ:ALMS Alumis Q4 2025 Earnings Results & Report $6.62 +0.22 (+3.44%) Closing price 04:00 PM EasternExtended Trading$6.42 -0.20 (-3.02%) As of 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Alumis missed analyst expectations on both earnings and revenue in its Q4 2025 results, released March 19, 2026. The company reported EPS of -$0.95 versus the -$0.90 consensus estimate, while revenue of $1.93 million fell short of the $2.75 million estimate by $821 thousand. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ4 2025Report DateMarch 19, 2026TimeBefore Market Opens Alumis EPS ResultsActual EPS-$0.95Consensus EPS -$0.90Beat/MissMissed by -$0.05One Year Ago EPSN/AEPS Beat Rate0 of last 7 quartersAlumis Revenue ResultsActual Revenue$1.93 millionExpected Revenue$2.75 millionBeat/MissMissed by -$821.00 thousandYoY Revenue GrowthN/AUpcoming EarningsAlumis' Q3 2026 earnings is estimated for Thursday, November 12, 2026, based on past reporting schedulesConference Call ResourcesPress Release (8-K)Annual Report (10-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Annual report(10-K) Alumis Q4 2025 Earnings FAQ Did Alumis beat earnings estimates for Q4 2025? Alumis (NASDAQ:ALMS) reported earnings of -$0.95 per share for Q4 2025, missing the consensus estimate of -$0.90. The report was announced on Thursday, March 19, 2026. What was Alumis' revenue for Q4 2025? Alumis reported revenue of $1.93 million for Q4 2025, against a consensus estimate of $2.75 million. When is Alumis' next earnings date? Alumis' next earnings date is estimated for Thursday, November 12, 2026. MarketBeat tracks confirmed and estimated earnings dates for Alumis on the company's earnings history page. Alumis Earnings HeadlinesAlumis (ALMS) Expected to Release Quarterly Earnings on ThursdayNovember 11 at 3:44 AM | americanbankingnews.comAlumis Inc. (NASDAQ:ALMS) Stock Has Consensus Price Target of $33.27November 6, 2026 | americanbankingnews.comGOP wipeout … but here's WORSE news for the marketA 3 trillion dollar crisis may be building beneath the surface of the stock market, retirement accounts, pensions, and even banks. Reuters reports alarm bells echoing 2007 subprime warnings, and bestselling author Dr. Martin Weiss says this one may already be underway. His free briefing outlines five steps investors are considering to help protect their portfolios.November 11 at 1:00 AM | Weiss Ratings (Ad)Alumis’ Phase 3 Psoriasis Trial Reaches Completion, Raising the Stakes for ALMS InvestorsOctober 28, 2026 | tipranks.comAlumis Caps Key Psoriasis Trial, Raising Stakes for ALMS InvestorsOctober 28, 2026 | tipranks.comAlumis Reports Positive Phase 3 Data With EnvudeucitinibOctober 9, 2026 | rttnews.comSee More Alumis Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Alumis? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Alumis and other key companies, straight to your email. Email Address About AlumisAlumis (NASDAQ:ALMS) is a clinical-stage biopharmaceutical company developing medicines for autoimmune and inflammatory diseases. The company uses data and computational tools to support the discovery and development of targeted treatments. Its lead investigational program, ESK-001, is an oral, selective TYK2 inhibitor being studied for conditions including plaque psoriasis and systemic lupus erythematosus. Alumis is also advancing other drug candidates for immune-mediated diseases. These medicines remain in clinical development and are not approved for commercial use. Alumis was formed in 2024 through the combination of Esker Therapeutics and Kintara Therapeutics and is based in South San Francisco, California. Its work includes conducting clinical trials and developing potential treatments for patients with inflammatory and autoimmune conditions.View Alumis ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Keeping AI Cool: AAON Rides the AI Heatwave to Record GrowthCan Constellation Energy's Contracts Power a Stock Rebound?IonQ Raised the Bar, But 3 Quantum Rivals Face Tough QuestionsAmazon's Rally Is Outpacing Big Tech, But Can AWS Justify the AI Spending?Aehr Test Systems Notches Another Post-Earnings Win as Sales Triple on AI DemandAST SpaceMobile Has a New Rocket Plan, But Its Cash-Burn Problem Isn't Going AwayPowering Up the Moon: Redwire’s $40 Million NASA Award Upcoming Earnings Brookfield (11/12/2026)NU (11/12/2026)Applied Materials (11/12/2026)Cisco Systems (11/12/2026)Mizuho Financial Group (11/13/2026)Mitsubishi UFJ Financial Group (11/13/2026)Sumitomo Mitsui Financial Group (11/13/2026)Home Depot (11/17/2026)Walt Disney (11/17/2026)NVIDIA (11/17/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
